- Price
- 1,650.00p
- Market cap
- £3.44bn
- 1M
- +5.5%
- 3M
- +9.8%
- 1Y
- -0.1%
- P/E (trailing)
- —
- Dividend yield
- —
“Strong momentum in our Branded and Hikma Rx businesses and growth in all our geographies enabled us to deliver Group revenue and profit growth in line with guidance”
operating profit
“We tighten our core operating profit range to $730 million to $750 million, in line with current market expectations, and updated from the previous range of $730 million to $770 million.”
operating profit
Last 24 months of trading updates, one verdict per announcement (the headline profit measure first). Companies report these themselves and lean positive, so compare against peers: the same tag-based peer group as the Overview, counting peers with at least 2 updates and needing at least 3. Verdicts are machine-extracted; where the quoted wording clearly says otherwise, the wording is used.
“Strong momentum in our Branded and Hikma Rx businesses and growth in all our geographies enabled us to deliver Group revenue and profit growth in line with guidance”
operating profit
“We tighten our core operating profit range to $730 million to $750 million, in line with current market expectations, and updated from the previous range of $730 million to $770 million.”
operating profit
Last 24 months of trading updates, one verdict per announcement (the headline profit measure first). Companies report these themselves and lean positive, so compare against peers: the same tag-based peer group as the Overview, counting peers with at least 2 updates and needing at least 3. Verdicts are machine-extracted; where the quoted wording clearly says otherwise, the wording is used.